Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 6/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.56 |
| ▸ | PDE9A | O76083 | 4/20 | 0.56 |
| ▸ | PDE5A | O76074 | 3/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365889 | 0.88 | PNP (0.44) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL6366302 | 0.86 | PDE1A (0.41) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL6374090 | 0.86 | PDE1A (0.48) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL6366342 | 0.86 | AR (0.42) | PDE1APDE1BPDE1CPDE9ACYP2C9 | |
| SCHEMBL6366723 | 0.85 | AR (0.39) | PDE1APDE1BPDE1CPDE9A | |
| SCHEMBL3493454 | 0.85 | PDE1C (0.57) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL6366319 | 0.83 | KDM4E (0.48) | PDE1APDE1BPDE1CPDE9A | |
| SCHEMBL6366854 | 0.83 | CCR2 (0.39) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL7039453 | 0.81 | PDE9A (0.61) | PDE1APDE1BPDE1CPDE9APDE5A | |
| SCHEMBL7039414 | 0.80 | PDE9A (0.59) | PDE1APDE1BPDE1CPDE9APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | claimed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | claimed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE1A 44/4885PDE1B 41/4885PDE1C 101/4885 |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PDE9A, PDE2A, PDE3A | PDE1A 62/4885PDE1B 50/4885PDE1C 42/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE1A 46/4885PDE1B 39/4885PDE1C 41/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE1A 46/4885PDE1B 39/4885PDE1C 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.